000280246 001__ 280246
000280246 005__ 20250831001818.0
000280246 0247_ $$2doi$$a10.1016/j.omtm.2025.101531
000280246 0247_ $$2pmid$$apmid:40741602
000280246 0247_ $$2pmc$$apmc:PMC12309954
000280246 0247_ $$2altmetric$$aaltmetric:179392244
000280246 037__ $$aDZNE-2025-00924
000280246 041__ $$aEnglish
000280246 082__ $$a610
000280246 1001_ $$0P:(DE-2719)9000818$$aWiora, Linus$$b0$$eFirst author
000280246 245__ $$aAAV8-based gene replacement therapy for hereditary spastic paraplegia type 5.
000280246 260__ $$aNew York, NY$$bNature Publishing Group$$c2025
000280246 3367_ $$2DRIVER$$aarticle
000280246 3367_ $$2DataCite$$aOutput Types/Journal article
000280246 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1754896090_31917
000280246 3367_ $$2BibTeX$$aARTICLE
000280246 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000280246 3367_ $$00$$2EndNote$$aJournal Article
000280246 520__ $$aHereditary spastic paraplegia type 5 (SPG5) is an autosomal recessive neurological disorder caused by mutations in the CYP7B1 gene, which encodes cholesterol 7α-hydroxylase, an essential enzyme in cholesterol metabolism. These mutations lead to elevated levels of 25- and 27-hydroxycholesterol, oxysterols known to be neurotoxic and blood-brain-barrier permeable. Their accumulation contributes significantly to SPG5 pathogenesis, resulting in spastic gait disturbance and severely impaired quality of life. Using a Cyp7b1-/- mouse model that mirrors the metabolic phenotype of SPG5, we developed a gene therapy approach to correct oxysterol imbalance. We designed an AAV8-TTR-hCYP7B1 vector to deliver the CYP7B1 gene specifically to the liver. Following intravenous administration, oxysterol levels in blood and liver were rapidly normalized, even at low doses (1E10), with no observed toxicity at the highest tested dose (1E11). Despite these promising peripheral results, oxysterol levels in the brain, particularly 27-hydroxycholesterol, remained only partially corrected six weeks post-treatment. Our findings suggest that while liver-targeted gene therapy is effective at restoring peripheral cholesterol metabolism, a successful therapeutic strategy for SPG5 must also address central nervous system involvement. We conclude that successful treatment of SPG5 would require a novel gene therapeutic approach that also targets the CNS.
000280246 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000280246 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000280246 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000280246 650_7 $$2Other$$aAAV
000280246 650_7 $$2Other$$aCYP7B1
000280246 650_7 $$2Other$$aSPG5
000280246 650_7 $$2Other$$acholesterol
000280246 650_7 $$2Other$$agene therapy
000280246 650_7 $$2Other$$ahereditary spastic paraplegia
000280246 650_7 $$2Other$$aneurodegeneration
000280246 650_7 $$2Other$$aoxysterols
000280246 7001_ $$aYuan, Qinggong$$b1
000280246 7001_ $$aHook, Sebastian$$b2
000280246 7001_ $$aKraft, Melanie$$b3
000280246 7001_ $$aBjörkhem, Ingemar$$b4
000280246 7001_ $$aOtt, Michael$$b5
000280246 7001_ $$0P:(DE-2719)2810998$$aHauser, Stefan$$b6$$udzne
000280246 7001_ $$0P:(DE-2719)2810795$$aSchöls, Ludger$$b7$$eLast author$$udzne
000280246 773__ $$0PERI:(DE-600)2863173-0$$a10.1016/j.omtm.2025.101531$$gVol. 33, no. 3, p. 101531 -$$n3$$p101531$$tMolecular therapy / Methods & clinical development$$v33$$x2329-0501$$y2025
000280246 8564_ $$uhttps://pub.dzne.de/record/280246/files/DZNE-2025-00924.pdf$$yOpenAccess
000280246 8564_ $$uhttps://pub.dzne.de/record/280246/files/DZNE-2025-00924%20SUP.zip
000280246 8564_ $$uhttps://pub.dzne.de/record/280246/files/DZNE-2025-00924.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000280246 909CO $$ooai:pub.dzne.de:280246$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000280246 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000818$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000280246 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810998$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000280246 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810795$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000280246 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000280246 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000280246 9141_ $$y2025
000280246 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-06
000280246 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-06
000280246 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-06
000280246 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-06
000280246 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000280246 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOL THER-METH CLIN D : 2022$$d2024-12-06
000280246 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-09-18T08:12:17Z
000280246 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-09-18T08:12:17Z
000280246 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-06
000280246 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-06
000280246 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-06
000280246 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-06
000280246 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000280246 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-09-18T08:12:17Z
000280246 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-06
000280246 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-06
000280246 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-06
000280246 9201_ $$0I:(DE-2719)5000005$$kAG Schöls$$lClinical Neurogenetics$$x0
000280246 9201_ $$0I:(DE-2719)1210016$$kAG Hauser$$lAdvanced cellular models of neurodegeneration$$x1
000280246 980__ $$ajournal
000280246 980__ $$aVDB
000280246 980__ $$aUNRESTRICTED
000280246 980__ $$aI:(DE-2719)5000005
000280246 980__ $$aI:(DE-2719)1210016
000280246 9801_ $$aFullTexts